Archived Content

Final Days to Register!


Small molecule drug discovery has approached a critical junction where the rigorous pre-clinical validation and prioritizing of novel targets is of utmost importance. Challenged with thinning development pipelines and significant losses in revenue, greater emphasis is being placed on the stringent selection and validation of targets and candidate molecules to increase success and reduce attrition rates in phase II trials. In response to this challenge, a synergy between drug discovery and chemical biology is emerging as a vital component to providing adequate confidence before launching full discovery programs. The development and utilization of high-quality chemical probes in combination with disease-relevant phenotypic systems provides a powerful approach to obtain a deeper interrogation of target-phenotype relationships - ultimately enriching target validation.

Cambridge Healthtech Institute is proud to announce the Inaugural Chemical Biology for Target Validation conference, established to convene an interdisciplinary collection of leaders in chemical/structural biology, chemical proteomics, medicinal chemistry, synthetic chemistry and chemogenomics to discuss strategies to de-risk novel discovery initiatives.


Stuart SchreiberSelecting and Modulating Therapeutic Targets Using Human Biology and Chemical Biology

Stuart L. Schreiber, Ph.D., Director, Center for the Science of Therapeutics & Founding Member, Broad Institute of Harvard and MIT; Howard Hughes Medical Institute Investigator; Morris Loeb Professor, Chemistry and Chemical Biology, Harvard University


Chas BountraStructures, Chemical Probes, New Biology, New Targets for Drug Discovery: Is This the Right Sequence? 

Chas Bountra, Ph.D., Professor, Translational Medicine; Head, Structural Genomics Consortium, University of Oxford 


Nathanael GrayCovalent Inhibitors of Oncogenic Signaling Pathways

Nathanael Gray, Ph.D., Professor, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; Professor, Cancer Biology, Dana-Farber Cancer Institute 


JamesBradnerGenome-Wide Spatial Localization of Small Molecules 

James E. Bradner, M.D., Assistant Professor, Department of Medicine, Harvard Medical School and Investigator, Department of Medical Oncology, Dana-Farber Cancer Institute




  • Academic-Industry Strategies to De-Risk Discovery Initiatives
  • Utilization of Human Genetics and Chemical Biology for Target Validation
  • Case Studies in Epigenetics, Protein-Protein Interactions and Novel Biology
  • Phenotypic Screening, Target Identification and MOA of Novel Compounds
  • Chemical Tools and Strategies to Modulate Biological Processes
  • Technological Advances Enabling Target Validation
  • Interaction with Over 500 Attendees during Networking Breaks and Poster Sessions


  • AstraZeneca
  • Boston College
  • Bristol-Myers Squibb
  • Dana-Farber Cancer Institute
  • Emory University
  • H3 Biomedicine
  • Harvard University
  • HYBRiGENiCS Services
  • Indiana University 
  • Intelligent Pharma
  • Karolinska Institute
  • Massachusetts General Hospital
  • Memorial Sloan–Kettering
  • Novartis
  • Pelago Bioscience AB
  • Pfizer
  • SGC Oxford
  • SRI International 
  • The Broad Institute
  • The University of British Columbia  

Day 1 | Day 2